BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Deep Genomics Releases AI Foundation Model for microRNA Binding and mRNA Degradation Prediction

by BiopharmaTrend   •   May 26, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Deep Genomics has introduced REPRESS, a deep learning model trained to predict microRNA (miRNA) binding and mRNA degradation directly from nucleotide sequence—two core mechanisms that determine mRNA stability and influence protein levels. The model is described as the first foundation model to address these post-transcriptional events from sequence alone, and is now integrated into Deep Genomics’ multi-model Foundation Model Platform.

#advertisement
AI in Drug Discovery Report 2025

REPRESS was trained on millions of experimentally validated sites from human and mouse tissues. According to the company, it outperforms seven existing methods across multiple benchmarks, including variant effect prediction and both canonical and non-canonical repression modeling. It is designed to support antisense oligonucleotide (ASO), siRNA, and mRNA therapeutic programs by enabling more precise target selection and modulation of gene expression.

The model complements Deep Genomics’ prior work on RNA splicing and editing, forming what the company describes as a cohesive, interoperable AI platform for end-to-end genomic R&D. 

The REPRESS model is now available for non-commercial academic use via GitHub, allowing external researchers to explore mRNA stability mechanisms in disease and drug development contexts.

bioRxiv source: https://www.biorxiv.org/content/10.1101/2025.05.15.654105v1

Deep Genomics

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.